The delay for the phase 1 clinical trial was already announced...

The delay for the phase 1 clinical trial was already announced on the 31st August :

"Manufacturing of MAP 315 with Microba’s partner in Europe continues to make progress, however issues with a piece of
processing equipment required for cGMP production of clinical material have resulted in some minor delays. A complete
solution is being deployed by the Company’s partner butrequires additional time for implementation and cGMP qualification.
This extends the timeline to receive cGMP material to initiate dosing for Microba’s Phase I clinical trial from December 2022,
into April 2023. The additional time will also be leveraged to gather additional supporting data and conduct further process
development activities to advance manufacturing efficiency."

The Swiss let us down but all good now.

Great to see the slide with milestone timelines over the next quarters.

Close to cash backing now. Crazy stuff considering our high growth testing business that is clearly expanding which only increases the value of the Microba data bank. Then on top of that we have several therapeutic programs progressing plus a big pharma transaction (valued in 100's of million of US$) which could drop at any time.

The new significant service distribution partners take about 6 months to on board and start ramping up so I wouldn't expect any significant growth in revenues until 1st half next year. From there it should ramp up considerably with all the new additional partners being added. I understand we need about $10 mil in revenue to obtain breakeven in the services business and we should achive that run rate by mid next year imo. With 90% gross profit margin this business will start to become a huge cash cow.

Still a few funds on board looking to get out due to their own liquidity issues.
Another decent crossing today.

Looking forward to catching up with Dr Luke Reid at the upcoming Tech Know conferences in Sydney and melbourne.